Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

575
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
575
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

506
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
506
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

566
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
566
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

460
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
460
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

613
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
613
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

358
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
358

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient perspectives to inform the implementation of tobacco use treatment in Lebanon's safety net primary care system: a qualitative study.

BMJ open·2026
Same author

Observations of the Gas Phase Composition of the 2024 BioLab Industrial Plume in the Atlanta Metropolitan Area.

Environmental science & technology letters·2026
Same author

Fate of isoprene peroxy radical constrains the urban photochemical regime.

Science advances·2026
Same author

Peripheral Regulatory T Cells Display Dynamic Memory Subset Frequency and Inhibitory Marker Expression Across Pregnancy.

American journal of reproductive immunology (New York, N.Y. : 1989)·2026
Same author

Higher Levels of Cardiovascular Biomarkers Following Hypertensive Compared to Normotensive Pregnancy.

Pregnancy (Hoboken, N.J.)·2026
Same author

Integrating Social and Clinical Determinants of Pre-Eclampsia: A Hierarchical Systematic Review and Conceptual Framework for Prevention.

BJOG : an international journal of obstetrics and gynaecology·2026

Related Experiment Video

Updated: Feb 7, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Cardiomyopathy and Preeclampsia.

Hilary S Gammill1,2, Rakesh Chettier3, Alina Brewer3,4

  • 1Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Washington, Seattle (H.S.G., R.S.).

Circulation
|July 20, 2018
PubMed
Summary

Preeclampsia is linked to gene mutations causing cardiomyopathy, especially in the TTN gene. These findings suggest a genetic basis for cardiovascular risks in preeclampsia patients.

Keywords:
cardiomyopathiescardiovascular diseasesgeneticspreeclampsia

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Related Experiment Videos

Last Updated: Feb 7, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Area of Science:

  • Cardiovascular Genetics
  • Reproductive Medicine
  • Genomic Medicine

Background:

  • Preeclampsia is associated with maternal cardiovascular diseases, including diastolic dysfunction and cardiomyopathy.
  • Gene mutations linked to idiopathic cardiomyopathy have been implicated in peripartum cardiomyopathy.
  • The role of cardiomyopathy gene mutations in preeclampsia remains unclear.

Purpose of the Study:

  • To investigate whether cardiomyopathy gene mutations contribute to the development of preeclampsia.
  • To identify specific gene variants associated with preeclampsia in a patient cohort.

Main Methods:

  • Whole exome sequencing was performed on 181 preeclampsia subjects and compared to control groups.
  • Rare variants (MAF <0.1%) in 43 cardiomyopathy genes were analyzed.
  • Loss-of-function and damaging missense variants were identified and quantified.

Main Results:

  • Preeclampsia subjects showed a significantly higher prevalence of rare loss-of-function variants (5.5% vs 2.5%) in cardiomyopathy genes compared to controls (P=0.014).
  • Sixty-eight percent of preeclampsia patients carried at least one loss-of-function or damaging missense variant.
  • The TTN gene harbored the majority of mutations (55%), with 73% of preeclampsia subjects having TTN mutations versus 48% in controls (P=1.36E-11).

Conclusions:

  • Women with preeclampsia are more likely to carry protein-altering mutations in cardiomyopathy-associated genes, particularly TTN.
  • These mutations are prevalent across preeclampsia, idiopathic cardiomyopathy, and peripartum cardiomyopathy, indicating a broader role in cardiovascular disorders.
  • Identifying these variants can improve diagnosis, classification, counseling, and management of at-risk women.